Announcements Trials
Browse Landscape

Phase

Phase 2 80Phase 3 37Phase NA 19Phase 2/3 11Phase 1/2 7Phase 1 7Phase EARLY_PHASE1 2Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 21Capecitabine 19Fluorouracil 16Bevacizumab 15Esomeprazole 11Sorafenib 10Irinotecan 9Leucovorin 8Radiofrequency Ablation 7Propofol 7Bismuth 7Morphine 6Folfox protocol 6Amoxicillin 6lenvatinib 5gadolinium ethoxybenzyl DTPA 5Tetracycline 5Sevoflurane 5S 1 (combination) 5Gemcitabine 5Drug Therapy 5Control Groups 5sodium glycididazole 4fish oil triglycerides 4ferric carboxymaltose 4Ribavirin 4Hepatectomy 4HMPL-013 4Golytely 4Furazolidone 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoadjuvant Therapy × Gastrointestinal × Clear all
NCT06003673 2023-10-24

A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC

First Affiliated Hospital of Fujian Medical University

Phase 4 Unknown
20 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡